Therapeutic mRNA Patent Monitoring Service 2024: Track Competitors' IP Activities and their Future Intentions
Wednesday, April 10, 2024
DUBLIN, April 2, 2024 /PRNewswire/ -- The "Therapeutic mRNA Patent Monitor" newsletter has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The mRNA Therapeutics Patent Monitoring Service allows you to take advantage of a quarterly-updated Excel file and benefit from both quarterly analysis reports and direct interaction with the publisher's analysts.
The directory includes new patent applications, new granted patents, patents expired/abandoned, patent transfers (re-assignment, licensing), and patent litigation/opposition. The patents are categorized by technology segments, including mRNA design (self-amplifying and circular RNA), carriers, manufacturing, and storing process, but also by application and therapeutic area.
The success of mRNA vaccines as a response to the COVID-19 pandemic has shone a light on the disruptive aspect of mRNA-based therapeutic technology. COVID-19 is one of many indications for the mRNA technology platform, which holds high promise for new vaccines with a wide spectrum of microbial pathogens and cancers. Moreover, therapeutic mRNA is not limited to vaccination, but has also been developed to treat both rare and common diseases (genetic diseases, fibrotic diseases, autoimmune disorders, etc.). However, a series of challenges remain to be addressed before mRNA can be established as a general therapeutic modality.
An array of new technologies is being developed to surmount these challenges, including approaches to optimize mRNA cargos, carriers with inherent tissue tropism, and mRNA storing, for example. The orientation of future development might also depend on the therapeutic application, as the development pathway for mRNA vaccines and therapeutics differs in several important respects, such as mRNA immunogenicity,tissue tropism, delivery, or pharmacokinetics. In this fast-evolving context, it is crucial to understand the intellectual property position and strategy of the different players. Such knowledge can help detect business risks and opportunities, identify emerging research areas, and understand competitors'strategies.
This useful Excel spreadsheet with hyperlinks to updated online database allows for multi-criteria searches, including priority date, patent assignees, legal status of patents, and specific segments. The quarterly PDF reports provide the IP trends over the last three months, with a close look at key IP players and patented technologies. Direct access to the publisher's analysts offers you on-demand Q&A sessions and open discussions regarding the quarterly report results, trends, analyses, specific patented technologies, or companies' patent portfolios in the field of Therapeutic mRNA.
BENEFITS OF THE PATENT MONITORING SERVICE
Keep an eye on your competitors' IP activities and their future intentions
With the help of the patent monitoring service, you will be aware of your competitors' current patenting activities, their IP dynamics, patent transfers including acquisitions and licenses, patent litigation, technology development, and R&D strategies. You will also be able to detect newcomers early in your business area.
Keep track of the latest technology developments and stay ahead of technology trends
By taking note of any recent patent filings, you can track the latest innovations in the field. You will get details on claimed inventions and you can follow technology developments. New technical solutions could inspire and improve your R&D activity.
Prevent registration of IP rights that may be harmful to your business
You will obtain information on patent applications filed even before exclusive rights have been granted, and you can react in time to prevent registration of IP rights that may be harmful to your business
React quickly to infringements and mitigate legal risks
Monitoring newly-issued patents allows you to regularly assess your freedom-to-operate, ensuring that your products or processes are not covered by patents and thus can be manufactured, sold, or used safely without infringing valid IP rights owned by others. Take advantage of free technologies and reduce R&D project risks. By tracking both expired patents and abandoned patents, you will be able to identify inventions entering the public domain that you can use safely for your development
Understand the current IP trends and IP strategy of competitors
On a quarterly basis, the report will provide the IP trends over the last three months, with a close look at key IP players, newcomers, and key patented technologies. Main patent applicants and their inventions, blocking patents, promising patents, and key newly expired or abandoned patents will be highlighted
Access an IP analyst
Take advantage of direct interaction with our analysts by phone and/or email and get specific input for specific patented technologies and companies' IP portfolios through on-demand Q&A sessions and discussion (100 hours per year).
Key features of the service
-- Every quarter an up-to-date Excel database
-- Featured image of Therapeutic mRNA patent monitor.
-- New patent applications
-- Patent applications newly granted
-- Expired or abandoned patents
-- Transfer of IP rights (re-assignment, licensing) and IP collaborations.
-- Patent litigations and oppositions
-- Patents categorized by technological segmentation, application and
therapeutic area: mRNA design, delivery, manufacturing, mRNA-based
vaccines, mRNA-based therapeutics, infectious diseases, oncological
disorders and other diseases.
-- Hyperlinks to updated online database (legal status, documents etc.)
Every quarter a PDF report including:
-- Key facts & figures of the quarter
-- Graphs and comments covering the patent landscape evolutions
-- A close look at the key IP players and newcomers
-- Access to an IP analyst for 100 hours per year:
-- Q&A sessions and discussions with our IP analysts regarding trends,
analyses, specific patented technologies, or companies' IP portfolios in
the field of mRNA therapeutics.
A selection of companies mentioned in this report includes, but is not limited to:
-- Abnova
-- Arcturus
-- Biontech
-- Celanese
-- Chimeron Bio
-- CirCode
-- Daiichi Sankyo
-- Dompe
-- Elanco
-- Gnereation Bio
-- Gritstone Bio
-- GSK
-- Inventage Lab
-- Leon
-- Magle Chemoswed
-- Moderna
-- Nanovation Therapeutics
-- nference
-- Pfizer
-- Renagade Therapeutics
-- Replicate
-- Sanofi
-- Therna Therapeutics
-- UreVac
-- WestGene BioPharma
For more information about this newsletter visit https://www.researchandmarkets.com/r/d3s0fq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/therapeutic-mrna-patent-monitoring-service-2024-track-competitors-ip-activities-and-their-future-intentions-302103810.html
SOURCE Research and Markets
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Buyers Edge Platform Appoints Jaime Selga to Lead Expansion Across the Middle East, Africa & Asia | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
|
